普伐他汀对高脂血症病人细胞黏附分子表达的影响

①目的　探讨普伐他汀对高脂血症病人细胞黏附分子表达的影响。②方法　 2 0例高脂血症病人应用普伐他汀治疗 8周 ,检测治疗前后白细胞CD18表达、血浆可溶性细胞间黏附分子 1(sICAM 1)和可溶性血管细胞间黏附分子 1(sVCAM 1)浓度及病人血脂变化。③结果　治疗 8周后 ,高脂血症病人白细胞CD18表达、sICAM 1和sVCAM 1浓度明显降低 ,与治疗前比较差异有显著性 (t=2 .5 95～ 4 .912 ,P <0 .0 5 ,0 .0 1) ;并且白细胞CD18表达、sICAM 1和sVCAM 1浓度均与血清总胆固醇含量呈正相关 (r =0 .5 88～ 0 .72 1,P <0 .0 1) ,与低密度脂蛋白胆固醇呈正相关 (r=0 .5 96～ 0 .75 3,P <0 .0 1) ,与高密度脂蛋白胆固醇呈负相关 (r =- 0 .4 6 2～ - 0 .6 12 ,P <0 .0 5 ,0 .0 1)。④结论　普伐他汀可降低高脂血症病人细胞黏附分子水平。

EFFECTS OF PRAVASTATIN ON CELL ADHESION MOLECULES IN PATIENTS WITH HYPERLIPIDEMIA

Objective To investigate the effects of pravastatin on expression of cell adhesion molecule in patients with hyperlipidemia. Methods Twenty patients with hyperlipidemia were treated with pravastatin for 8 weeks. Before and after the treatment, the plasma leukocyte CD 18 expression, soluble intercellular adhesion molecule 1 (sICAM 1) and soluble vascular cell adhesion molecule 1 (sVCAM 1) were examined. Results After 8 week treatment, the leukocyte CD 18 expression, sICAM 1 and sVCAM 1 concentration were reduced significantly ( t=2.595-4.912,P <0.05,0.01). The leukocyte CD 18 expression, sICAM 1 and sVCAM 1 were positively correlated with TC ( r=0.588-0.721,P <0.01) and LDL C( r=0.596-0.753,P <0.01), but negatively with HDL C ( r=-0.462--0.612, P <0.05,0.01) . Conclusion Pravastatin can reduce cell adhesion molecule concentration in patients with hyperlipidemia.